Why a long Covid drug trial failed — and what's next

BC 007, a German infusion that had lifted the hopes of patients, is heading for a new study.

July 22, 2025 Check out STAT+

Sponsored By

Miles Griffis/The Sick Times A rare drug trial for long Covid failed, yielding lessons on study design The failed drug trial of BC 007 for long Covid reveals the need for better study design, patient-centered research, and focused strategies. By Betsy Ladyzhets — The Sick Times Study of GLP-1 guidelines for teens points to potential for influence from drugmakers More than one-third of people who developed guidelines for treating children with obesity had financial ties to obesity drugmakers, a paper finds. By Isabella Cueto STAT+ | Sarepta Therapeutics' Duchenne therapy faces 'arduous' path back to market, senior FDA official says FDA insider suggests Sarepta's gene therapy for Duchenne muscular dystrophy may never return to market. By Adam Feuerstein and Jason Mast Molly Ferguson for STAT STAT+ | Drugmakers are racing to help patients stay awake — and could also make billions Takeda, Alkermes, and Centessa lead a race to develop orexin drugs that could transform narcolepsy treatment and tackle a range of other sleep issues. By Elaine Chen STAT+ | Replimune skin cancer therapy rejected by FDA, a sign of regulators' hardened stance The FDA's decision is the latest indication that the agency is taking a hardened stance on drug approvals under regulatory Vinay Prasad. By Adam Feuerstein STAT+ | Sanofi to buy vaccine biotech Vicebio for $1.15B upfront Vicebio's lead candidate is designed to protect against both RSV and human metapneumovirus, known as hMPV. By Andrew Joseph Michael M. Santiago/Getty Images Opinion: Pioneer HIV researcher Robert Gallo: Cuts to medical research funding leave us vulnerable to viral threats Science alone can't stop a future pandemic. It requires support, investment, and trust, writes HIV pioneer Robert C. Gallo. By Robert C. Gallo STAT+ | Humana refiles Medicare Advantage ratings lawsuit against federal government A judge dismissed Humana's initial lawsuit against the government on procedural grounds. Billions of dollars are at stake for the insurer. By Bob Herman Opinion: The quick return of medical debt to credit reports is another blow to cancer patients Medical debt isn't accrued irresponsibly; it's accrued out of necessity. Nobody chooses cancer, and nobody chooses medical debt. By Gwen Nichols

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser